Abstract
Response rates to rituximab (RTX) range from 30-75% for Waldenström’s macroglobulinaemia (WM) patients. RTX can generate a transient IgM flare in some patients. Our study aimed to characterize this phenomenon using novel Hevylite® assays to specifically quantify IgMKappa and IgMLambda (IgMK, IgML).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
